Korro Bio (KRRO) Total Non-Current Liabilities (2021 - 2026)
Korro Bio's (KRRO) quarterly Total Non-Current Liabilities came in at $62.5 million in Q1 2026, up 1.16% YoY from $61.8 million in Q1 2025, and up 3.2% on a QoQ basis from $60.6 million in Q4 2025.
Korro Bio (KRRO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Korro Bio (KRRO) has 6 years of Total Non-Current Liabilities data on file, last reported at $62.5 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 1.16% year-over-year to $62.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.5 million (up 1.16% YoY) and the FY2025 annual result came in at $60.6 million, down 5.85% from the prior year.
- Total Non-Current Liabilities grew to $62.5 million in Q1 2026, from $60.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $64.4 million in Q4 2024 to a low of $8.9 million in Q4 2022.
- A 5-year average of $49.7 million and a median of $53.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 83.64% — and 2024, when it soared 557.45%.
- Tracing KRRO's Total Non-Current Liabilities over 5 years: stood at $8.9 million in 2022, then soared by 469.01% to $50.7 million in 2023, then climbed by 26.93% to $64.4 million in 2024, then slipped by 5.85% to $60.6 million in 2025, then grew by 3.2% to $62.5 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $62.5 million (Q1 2026), $60.6 million (Q4 2025), and $61.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | 58.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.72 Mn |
| Mar 31, 2026 | 62.53 Mn |
| Dec 31, 2025 | 60.59 Mn |
| Sep 30, 2025 | 60.99 Mn |
| Jun 30, 2025 | 63.88 Mn |
| Mar 31, 2025 | 61.81 Mn |
| Dec 31, 2024 | 64.35 Mn |
| Sep 30, 2024 | 63.19 Mn |
| Jun 30, 2024 | 50.33 Mn |
| Mar 31, 2024 | 45.73 Mn |
| Dec 31, 2023 | 50.70 Mn |
| Sep 30, 2023 | 9.61 Mn |
| Jun 30, 2023 | 33.98 Mn |
| Mar 31, 2023 | 48.25 Mn |
| Dec 31, 2022 | 8.91 Mn |
| Sep 30, 2022 | 53.96 Mn |
| Jun 30, 2022 | 53.74 Mn |
| Mar 31, 2022 | 52.21 Mn |
| Dec 31, 2021 | 54.45 Mn |
| Sep 30, 2021 | 54.79 Mn |